Scandinavian ChemoTech (Q3 Initial take): Another quarter with triple-digit growth - Redeye

Redeye provides an initial comment on Scandinavian ChemoTech’s Q3 2025 report. In short, the report showed continued triple-digit sales growth, in line with our estimates, and maintained cost control. EBIT landed at cSEK-1.1m, which was better than we had anticipated. With a 90% gross margin in the quarter, cash flow breakeven should be imminent if the current momentum is maintained. We expect to largely maintain our estimates following the report.

Länk till analysen i sin helhet: https://www.redeye.se/research/1135153/scandinavian-chemotech-q3-initial-take-another-quarter-with-triple-digit-growth?utm_source=finwire&utm_medium=RSS